N. Baudson

发表

A Comprehensive Preclinical Model Evaluating the Recombinant PRAME Antigen Combined With the AS15 Immunostimulant to Fight Against PRAME-expressing Tumors

C. Gerard, J. Louahed, L. Segal, 2015, Journal of immunotherapy.

Recombinant human papillomavirus type 16 E7 protein as a model antigen to study the vaccine potential in control and E7 transgenic mice.

D. Pardoll, C. Gerard, K. Kraemer, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Non‐clinical safety evaluation of single and repeated intramuscular administrations of MAGE‐A3 Cancer Immunotherapeutic in rabbits and cynomolgus monkeys

C. Gerard, N. Garçon, R. Forster, 2015, Journal of applied toxicology : JAT.

Comparative in vitro and in vivo cytotoxic activity of (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU) and its arabinosyl derivative, (E)-5-(2-bromovinyl)-1-β-D-arabinofuranosyluracil (BVaraU), against tumor cells expressing either the Varicella zoster or the Herpes simplex virus thymidine kinase

T. Velu, B. Degrève, J. Balzarini, 2000, Cancer Gene Therapy.

Tumor Mouse Model Confirms MAGE-A3 Cancer Immunotherapeutic As an Efficient Inducer of Long-Lasting Anti-Tumoral Responses

C. Gerard, J. Louahed, N. Baudson, 2014, PloS one.

Immunogenicity and safety of a combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course and a booster dose in healthy children in Russia: a phase III, non-randomized, open-label study

S. Kuriyakose, N. Meyer, Winnie Janssens, 2020, Human vaccines & immunotherapeutics.

Immunogenicity, safety, and reactogenicity of combined reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine administered as a booster vaccine dose in healthy Russian participants: a phase III, open-label study

L. Cámpora, N. Meyer, A. Asatryan, 2020, Human vaccines & immunotherapeutics.

Loss of tumorigenicity and increased immunogenicity induced by interleukin-10 gene transfer in B16 melanoma cells.

M. Goldman, C. Bruyns, C. Gerard, 1996, Human gene therapy.

Role and expression of CD40 on human retinal pigment epithelial cells.

C. Bruyns, T. Velu, C. Dubois, 2000, Investigative ophthalmology & visual science.

Curative potential of herpes simplex virus thymidine kinase gene transfer in rats with 9L gliosarcoma.

S. Goldman, B. Pirotte, J. Brotchi, 1996, Human gene therapy.

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells

N. Spector, Wenle Xia, Leihua Liu, 2005, Oncogene.

Non‐clinical safety evaluation of repeated intramuscular administration of the AS15 immunostimulant combined with various antigens in rabbits and cynomolgus monkeys

C. Gerard, C. Kuper, N. Garçon, 2015, Journal of applied toxicology : JAT.

Nonclinical reproductive and developmental safety evaluation of the MAGE-A3 Cancer Immunotherapeutic, a therapeutic vaccine for cancer treatment.

C. Gerard, N. Garçon, R. Forster, 2015, Reproductive toxicology.

Therapeutic potential of protein and adjuvant vaccinations on tumour growth.

D. Pardoll, C. Gerard, N. Garçon, 2001, Vaccine.

Seroprevalence of Bordetella pertussis Infection in Patients With Chronic Obstructive Pulmonary Disease in England: Analysis of the AERIS Cohort

Piyali Mukherjee, T. Wilkinson, N. Meyer, 2021, COPD.

The role of cellular- and prodrug-associated factors in the bystander effect induced by the Varicella zoster and Herpes simplex viral thymidine kinases in suicide gene therapy

T. Velu, C. Grignet-Debrus, C. Calberg‐Bacq, 2000, Cancer Gene Therapy.

118 POSTER Comprehensive preclinical model evaluating a protein-based MAGE-A3 specific cancer immunotherapy to fight against MAGE-A3 expressing tumors

C. Gerard, V. Brichard, N. Baudson, 2006 .